The Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)1 found that, in patients with schizophrenia whose medication was changed for clinical reasons, first (FGA)- and second (SGA)-generation antipsychotics were associated with comparable 1-year outcomes on measures of clinical improvement, adverse effects, quality of life, and costs of care. We have several concerns about the study:
Andrade C, Kharawala S. First- vs Second-Generation Antipsychotic Drugs in Schizophrenia. Arch Gen Psychiatry. 2007;64(8):978–979. doi:10.1001/archpsyc.64.8.978-b
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: